MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ghir.2019.12.005

Медицинская библиотека · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2019

A novel heterozygous STAT5B variant in a patient with short stature and partial growth hormone insensitivity (GHI).

Ramírez Laura, Sanguineti Nora, Scaglia Paula, Keselman Ana, Ballerini María Gabriela, Karabatas Liliana, Landi Estefanía, Castro Julia, Domené Sabina, Pennisi Patricia, Jasper Héctor, Rey Rodolfo A, Vázquez Martín, Domené Horacio, Bergadá Ignacio, Gutiérrez Mariana

Клинический случайСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

The most frequent monogenic causes of growth hormone insensitivity (GHI) include defects in genes encoding the GH receptor itself (GHR), the signal transducer and activator of transcription (STAT5B), the insulin like-growth factor type I (IGF1) and the acid-labile subunit (IGFALS). GHI is characterized by a continuum of mild to severe post-natal growth failure.

OBJECTIVE

To characterize the molecular defect in a patient with short stature and partial GHI.

PATIENT AND

METHODS

The boy was born at term adequate for gestational age from non-consanguineous normal-stature parents. At 2.2 years, he presented proportionate short stature (height -2.77 SDS), wide forehead and normal mental development. Whole-exome analysis and functional characterization (site-directed mutagenesis, dual luciferase reporter assay, immunofluorescence and western immunoblot) were performed.

RESULTS

Biochemical and endocrinological evaluation revealed partial GH insensitivity with normal stimulated GH peak (7.8 ng/mL), undetectable IGF1 and low IGFBP3 levels. Two heterozygous variants in the GH-signaling pathway were found: a novel heterozygous STAT5B variant (c.1896G>T, p.K632N) and a hypomorphic IGFALS variant (c.1642C>T, p.R548W). Functional in vitro characterization demonstrated that p.K632N-STAT5b is an inactivating variant that impairs STAT5b activity through abolished phosphorylation. Remarkably, the patient's immunological evaluation displayed only a mild hypogammaglobulinemia, while a major characteristic of STAT5b deficient patients is severe immunodeficiency.

CONCLUSIONS

We reported a novel pathogenic inactivating STAT5b variant, which may be associated with partial GH insensitivity and can present without severe immunological complications in heterozygous state. Our results contribute to expand the spectrum of phenotypes associated to GHI.

Для цитирования: Ramírez Laura, Sanguineti Nora, Scaglia Paula, Keselman Ana, Ballerini María Gabriela, Karabatas Liliana, Landi Estefanía, Castro Julia, Domené Sabina, Pennisi Patricia, Jasper Héctor, Rey Rodolfo A, Vázquez Martín, Domené Horacio, Bergadá Ignacio, Gutiérrez Mariana. A novel heterozygous STAT5B variant in a patient with short stature and partial growth hormone insensitivity (GHI).. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2019. DOI: 10.1016/j.ghir.2019.12.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.